These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35429037)

  • 1. Letter: association between COVID-19 and inflammatory bowel disease-Authors' reply.
    Hadi Y; Kochhar GS
    Aliment Pharmacol Ther; 2022 May; 55(9):1228-1229. PubMed ID: 35429037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Letter: paying attention to the comorbidities or extraintestinal complications in patients with inflammatory bowel disease during the COVID-19 pandemic-authors' reply.
    Hadi Y; Kochhar GS
    Aliment Pharmacol Ther; 2022 Jul; 56(1):178. PubMed ID: 35689315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letter: inflammatory bowel disease services during the Covid-19 pandemic - authors' reply.
    Deputy M; Hart A; Faiz O
    Aliment Pharmacol Ther; 2022 Apr; 55(8):1064. PubMed ID: 35362132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters. Authors' reply.
    Kokkotis G; Kitsou K; Bamias G
    Aliment Pharmacol Ther; 2022 May; 55(9):1235-1236. PubMed ID: 35429035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial: COVID-19 vaccines are safe and effective in patients with inflammatory bowel disease-but many unanswered questions remain. Authors' reply.
    Bhurwal A; Mutneja H; Seril D
    Aliment Pharmacol Ther; 2022 Jul; 56(1):164-165. PubMed ID: 35689313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter: SARS-CoV-2 infection in two inflammatory bowel disease patients treated with dual targeted therapy-Authors' reply.
    Al-Ani AH; Prentice RE; Rentsch C; Christensen B
    Aliment Pharmacol Ther; 2021 Mar; 53(6):766-767. PubMed ID: 33599326
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter: pancreatic involvement in inflammatory bowel disease-authors' reply.
    Massironi S; Viganò C; Danese S
    Aliment Pharmacol Ther; 2022 Jul; 56(2):371. PubMed ID: 35748849
    [No Abstract]   [Full Text] [Related]  

  • 8. Letter: IBD nurse-pivotal role in the time of the pandemic. Authors' reply.
    Al-Ani AH; Rentsch CA; Azim S; Bidgood E; Onasseril P; Christensen B
    Aliment Pharmacol Ther; 2020 Aug; 52(4):746-747. PubMed ID: 32886366
    [No Abstract]   [Full Text] [Related]  

  • 9. Letter: the effect of anti-COVID-19 treatment on the outcome of patients with inflammatory bowel disease-authors' reply.
    Hadi Y; Kochhar GS
    Aliment Pharmacol Ther; 2022 Jul; 56(1):179. PubMed ID: 35689310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Authors' Reply to: 'COVID-19 in the IBD Population: The Need for Correct Nomenclature'.
    Attauabi M; Seidelin JB; Burisch J
    J Crohns Colitis; 2021 Jun; 15(6):1080. PubMed ID: 33215634
    [No Abstract]   [Full Text] [Related]  

  • 11. Letter: fighting the battle but losing the war-inflammatory bowel disease and venous thromboembolism. Authors' reply.
    Lee KE; Faye AS
    Aliment Pharmacol Ther; 2022 Nov; 56(9):1427-1428. PubMed ID: 36221160
    [No Abstract]   [Full Text] [Related]  

  • 12. Letter: loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease-authors' reply.
    Mahmoud R; Schultheiss JPD; Fidder HH; Oldenburg B
    Aliment Pharmacol Ther; 2022 Feb; 55(4):499-500. PubMed ID: 35092052
    [No Abstract]   [Full Text] [Related]  

  • 13. Letter: association between COVID-19 and inflammatory bowel disease.
    Chen HY; Wang SI; Chang R; Wei JC
    Aliment Pharmacol Ther; 2022 May; 55(9):1226-1227. PubMed ID: 35429026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letter: diagnostic delay in inflammatory bowel disease-Authors' reply.
    Pollok RC; Baillie S; Jayasooriya N; Blackwell J; Petersen I; Bottle A; Saxena S;
    Aliment Pharmacol Ther; 2023 May; 57(10):1205-1206. PubMed ID: 37094317
    [No Abstract]   [Full Text] [Related]  

  • 15. Letter: risk of inflammatory bowel disease is related to alcohol consumption as well as ACEIs and ARBs-authors' reply.
    Khalili H; Casey K
    Aliment Pharmacol Ther; 2022 Apr; 55(7):884. PubMed ID: 35315105
    [No Abstract]   [Full Text] [Related]  

  • 16. Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease and Letter: faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease. Authors' reply.
    Ahmed I; Greenwood R; Costello B; Ratcliffe N; Probert C
    Aliment Pharmacol Ther; 2016 Jun; 43(11):1241-2. PubMed ID: 27137729
    [No Abstract]   [Full Text] [Related]  

  • 17. Letter: fulminant onset complicated inflammatory bowel disease (IBD) - a unique subtype? Authors' reply.
    Jayasooriya N; Saxena S; Pollok RC
    Aliment Pharmacol Ther; 2023 May; 57(10):1194-1195. PubMed ID: 37094302
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevention of COVID-19 in patients with IBD - Authors' reply.
    Ding NS; An P; Dong W; Ding Y
    Lancet Gastroenterol Hepatol; 2020 Jul; 5(7):640-641. PubMed ID: 32553142
    [No Abstract]   [Full Text] [Related]  

  • 19. Letter: irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease - authors' reply.
    Diederen K; Hoekman DR; Benninga MA
    Aliment Pharmacol Ther; 2016 Aug; 44(3):309-10. PubMed ID: 27375102
    [No Abstract]   [Full Text] [Related]  

  • 20. Letter of Reply to "Response to: COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD Patients' Association".
    Costantino A; Noviello D; Costantino C; Vecchi M; Caprioli F
    Inflamm Bowel Dis; 2022 Mar; 28(4):e57-e58. PubMed ID: 34792603
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.